We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Circulating Microvesicle-Based Assay Is Potential Prostate Cancer Diagnostic

By LabMedica International staff writers
Posted on 26 May 2011
A circulating microvesicle ("cMV")-based test is a potentially powerful diagnostic tool for detecting prostate cancer.

cMVs are sub-cellular membrane-bound vesicles, ranging from 30 nm to 1,500 nm in size, that are found circulating in the blood and other body fluids. More...
They are released from various cell types under both normal and pathologic conditions, including cancer. Each population of cMV expresses an array of proteins which reflects its cell-of-origin.

Carisome Technology is a versatile blood-based, highly reproducible testing technology. The technology platform identifies and characterizes cMVs, creating disease-specific, cMV-based biosignatures, which can be made up of a combination of biomarkers. The unique cMV biosignature can then be used for the diagnosis, prognosis, and measurement of therapeutic response.

The assay that enables the isolation, capture, and characterization of cMVs specific to prostate cancer was developed by Caris Life Sciences (Dallas, TX, USA). It has potential to deliver more accurate diagnoses for men with prostate cancer than current methods.

A poster highlighting the potential of the circulating microvesicle (cMV)-based prostate cancer test was presented at the American Urological Association (AUA) 2011 Annual Meeting, which was held in Washington DC (USA) from May 14-19, 2011.

Related Links:

Caris Life Sciences



Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.